Get the Stockscreener App
1.68
7.01%
0.11
After Hours:
1.65
-0.03
-1.79%
Invivyd Inc Stock (IVVD) Latest News
Invivyd Inc (NASDAQ: IVVD) Stock Forecast: Bearish Views Expect -505.1 Percent Drop In 2025 - Stocks Register
Holdings of Invivyd Inc (IVVD) are aligned with the stars - SETE News
How does IVVD’s price to cash per share ratio compare in the market? - US Post News
IVVD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Invivyd Inc’s (IVVD) Stock: A Week-by-Week Analysis - The News Heater
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - The Manila Times
Invivyd Inc [IVVD] stock for 46,098 USD was sold by MCGUIRE TERRANCE - Knox Daily
Exploring High Growth Tech Stocks in the United States - Simply Wall St
Following A 407.69% Weekly Incline, Is It Still A Buy For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
HC Wainwright Issues Negative Estimate for Invivyd Earnings - Defense World
Top Small Cap Stocks Worth WatchingFebruary 03rd - MarketBeat
This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here. - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Invivyd (IVVD) Stock Rises Following Strategic Partnership - Stocks Telegraph
Invivyd tweaks COVID prophylactic playbook, teaming with NFL coach Jim Harbaugh for awareness drive - FiercePharma
Invivyd (NASDAQ:IVVD) Earns “Buy” Rating from HC Wainwright - Defense World
Brokers Offer Predictions for Invivyd FY2029 Earnings - Defense World
Invivyd Inc Reports Q4 2024 Revenue of $13.8 Million, Slightly B - GuruFocus.com
H.C. Wainwright maintains Buy rating on Invivyd stock at $10 target - MSN
(IVVD)Analyzing Invivyd's Short Interest - Benzinga
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold - The Manila Times
Football Legend Jim Harbaugh Joins Forces with Invivyd as COVID Deaths Surge: One American Lost Every 9 Minutes - StockTitan
Analysts’ Revisions Show Improving Sentiment For Invivyd Inc (NASDAQ: IVVD) - Stocks Register
D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD) - Defense World
I See The Bull Case For Invivyd, But I’m Not Married To It (NASDAQ:IVVD) - Seeking Alpha
Invivyd Tracks SARS-CoV-2 Evolution, Prepares for Future Variants - Contagionlive.com
A Guide To The Risks Of Investing In Invivyd Inc (IVVD) - Knox Daily
Invivyd’s Promising Developments in COVID-19 Therapeutics Support Buy Rating - TipRanks
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
It makes sense and dollars to buy Invivyd Inc (IVVD) stock - SETE News
Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative - Marketscreener.com
Invivyd, Inc. (NASDAQ:IVVD) Sees Large Increase in Short Interest - Defense World
Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 - MSN
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
News on Alternative monoclonal antibody for treatment of COVID-19 Spikes Invivyd, Inc. (Nasdaq: IVVD) to Top Gainer List - Investorideas.com newswire
A closer look at IVVD’s price-to-free cash flow ratio - US Post News
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps - Benzinga
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability - The Manila Times
Invivyd Announces Positive Phase 1/2 Clinical Data for - GlobeNewswire
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely? - Simply Wall St
Invivyd Inc (IVVD) Volatility Hits 11.66% – Here Is What You Should Do - Stocks Register
Adagio Therapeutics stock hits 52-week low at $0.38 - Investing.com
We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon - Yahoo Finance
Invivyd seeks FDA nod for COVID-19 treatment in immunocompromised - MSN
Invivyd’s (IVVD) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Invivyd seeks FDA nod for COVID-19 treatment in immunocompromised By Investing.com - Investing.com Australia
Invivyd's (IVVD) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromi - The Manila Times
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromi - Yahoo Finance
Invivyd, Inc. (NASDAQ:IVVD) Shares Bought by Barclays PLC - Defense World
Invivyd (NASDAQ:IVVD) vs. iTeos Therapeutics (NASDAQ:ITOS) Head-To-Head Comparison - Defense World
Adagio Therapeutics stock hits 52-week low at $0.4 - Investing.com
D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD) - Defense World
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):